Sumitomo Mitsui DS Asset Management Company Ltd Has $19.82 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 3.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 781,952 shares of the biopharmaceutical company's stock after buying an additional 25,552 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Pfizer were worth $19,815,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Rialto Wealth Management LLC acquired a new position in Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer in the 4th quarter valued at approximately $30,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Pfizer stock traded up $0.79 during mid-day trading on Tuesday, hitting $25.03. The company's stock had a trading volume of 59,108,874 shares, compared to its average volume of 41,457,247. The stock has a market capitalization of $142.30 billion, a P/E ratio of 18.14, a P/E/G ratio of 0.88 and a beta of 0.57. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock's fifty day moving average price is $23.51 and its two-hundred day moving average price is $24.83. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the previous year, the firm posted $0.82 EPS. The company's quarterly revenue was down 7.8% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.87%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is 124.64%.

Analysts Set New Price Targets

A number of brokerages have issued reports on PFE. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.